Different effects of selective dopamine uptake inhibitors, GBR 12909 and WIN 35428, on HIV-1 Tat toxicity in rat fetal midbrain neurons

NeuroToxicology

Volumn 29, Issue 6, 2008, Pages 971-977

  Aksenov, Michael Y ^a   Aksenova, Marina V ^a   Silvers, Janelle M ^a   Mactutus, Charles F ^a   Booze, Rosemarie M ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cell culture; Cocaine; Dopamine transporter; HIV 1 Tat; Neurotoxicity

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; COCAINE; DOPAMINE; NISOXETINE; SERTRALINE; TRANSACTIVATOR PROTEIN; VANOXERINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOHISTOCHEMISTRY; MESENCEPHALON; NERVE CELL CULTURE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CELL SURVIVAL; CELLS, CULTURED; COCAINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; DRUG INTERACTIONS; EMBRYO, MAMMALIAN; HIV ENVELOPE PROTEIN GP120; MESENCEPHALON; NEURONS; PIPERAZINES; PROTEIN BINDING; RATS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS 1; RATTUS;

EID: 56249109392     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuro.2008.06.003     Document Type: Article

References (48)

1. Aksenov M.Y., Hasselrot U., Wu G., Nath A., Anderson C., Mactutus C.F., et al. Temporal relationships between HIV-1 Tat-induced neuronal degeneration, OX-42 immunoreactivity, reactive astrocytosis, and protein oxidation in the rat striatum. Brain Res 987 (2003) 1-9
2. Aksenov M.Y., Aksenova M.V., Nath A., Ray P.D., Mactutus C.F., and Booze R.M. Cocaine-mediated enhancement of Tat toxicity in rat hippocampal cell cultures: the role of oxidative stress and D1 dopamine receptor. Neurotoxicology 27 (2006) 217-228
3. Aksenova M.V., Silvers J.M., Aksenov M.Y., Nath A., Ray P.D., Mactutus C.F., et al. HIV-1 Tat neurotoxicity in primary cultures of rat midbrain fetal neurons: changes in dopamine transporter binding and immunoreactivity. Neurosci Lett 395 (2006) 235-239
4. Blakely R.D., De Felice L.J., and Hartzell H.C. Molecular physiology of norepinephrine and serotonin transporters. J Exp Biol 196 (1994) 263-281
5. Boos T.L., Greiner E., Calhoun W.J., Prisinzano T.E., Nightingale B., Dersch C.M., et al. Structure-activity relationships of substituted N-benzyl piperidines in the GBR series: synthesis of 4-(2-(bis(4-fluorophenyl) methoxy)ethyl)-1-(2-trifluoromethylbenzyl) piperidine, an allosteric modulator of the serotonin transporter. Bioorg Med Chem 14 (2006) 3967-3973
6. Bennett B.A., Hyde C.E., Pecora J.R., and Clodfelter J.E. Long-term cocaine administration is not neurotoxic to cultured fetal mesencephalic dopamine neurons. Neurosci Lett 153 (1993) 210-214
7. Chander G., Himelhoch S., and Moore R.D. Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs 66 (2006) 769-789
8. Chen F., Rezvani A.H., and Lawrence A.J. Autoradiographic quantification of neurochemical markers of serotonin, dopamine and opioid systems in rat brain mesolimbic regions following chronic St John's wort treatment. Naunyn-Schmiedeberg's Arch Pharmacol 367 (2003) 126-133
9. Chen N., Zhen J., and Reith M.E. Mutation of Trp84 and Asp313 of the dopamine transporter reveals similar mode of binding for GBR 12909 and benztropine as opposed to cocaine. J Neurochem 86 (2004) 853-864
10. Chen F., Larsen M.B., Neubauer H.A., Sanchez C., Plenge P., and Wiborg O. Characterization of an allosteric citalopram-binding at the serotonin transporter. J Neurochem 92 (2005) 21-28
11. Ferris M, Frederick-Duus D, Fadel J, Mactutus CF, Booze RM. Altered striatal dopamine transmission in rats exposed to the HIV-1 Tat protein and cocaine. In: Poster presented at the Society of Neuroimmune Pharmacology Meeting. Salt Lake City, UT; 2007.
12. Fiala M., Eshleman A.J., Cashman J., Lin J., Lossinsky A.S., Suarez V., et al. Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells. J Neurovirol 11 (2005) 281-291
13. Foster J.D., Cervinski M.A., Gorentla B.K., and Vaughan R.A. Regulation of the dopamine transporter by phosphorylation. Handb Exp Pharmacol 175 (2006) 197-214
14. In: Goslin K., Asmussen H., Banker G., Goslin K., and Banker G. (Eds). Culturing nerve cells. 2nd ed. (1998), MIT Press, Cambridge, MA 339-370
15. Gorentla B.K., and Vaughan R.A. Differential effects of dopamine and psychoactive drugs on dopamine transporter phosphorylation and regulation. Neuroparmacology 49 (2005) 759-768
16. Ingram S.L., Prasad B.M., and Amara S.G. Dopamine transporter-mediated conductances increase excitability of midbrain dopamine neurons. Nat Neurosci 5 (2002) 971-978
17. Jayanthi L.D., and Ramamoorthy S. Regulation of monoamine transporters: influence of psychostimulants and therapeutic antidepressants. AAPS J 7 (2005) E728-E738
18. Kendall S.L., Anderson C.F., Nath A., Turchan-Cholewo J., Land C.L., Mactutus C.F., et al. Gonadal steroids differentially modulate neurotoxicity of HIV and cocaine: testosterone and ICI 182,780 sensitive mechanism. BMC Neurosci 6 (2005) 40
19. Koe B.K., Lebel L.A., and Welch W.M. [3H] sertraline binding to rat brain membranes. Psychopharmacology 100 (1990) 470-476
20. Koutsiliery E., Sopper S., Scheller C., ter Meulen V., and Riederer P. Involvement of dopamine in the progression of AIDS dementia complex. J Neural Transm 109 (2002) 399-410
21. Manji H., and Miller R. Neurology of HIV infection. J Neurol Neurosurg Psychiatry 75 (2004) 29-35
22. Nath A., Anderson C., Jones M., Maragos W., Booze R., and Mactutus C. Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J Psychopharmacol 14 (2000) 222-227
23. Nath A., Hauser K.F., Wojna V., Booze R.M., Maragos W., Prendergast M., et al. Molecular basis for interactions of HIV and drugs of abuse. J Acquir Immune Defic Syndr 31 Suppl. 2 (2002) S62-S69
24. Navia B.A., Cho E.S., Petito C.K., and Price R.W. The AIDS dementia complex II. Neuropathology. Ann Neurol 19 (1986) 525-535
25. Ozdener H. Molecular mechanisms of HIV-1 associated neurodegeneration. J Biosci 30 (2005) 391-405
26. Prasad B.M., and Amara S.G. The dopamine transporter in mesencephalic cultures is refractory to physiological changes in membrane voltage. J Neurosci 21 (2001) 7561-7567
27. 3H]GBR 12935 binding. Mol Pharmacol 46 (1993) 125-135
28. Ravna A.W., Sylte I., and Dahl S.G. Molecular model of the neural dopamine transporter. J Comput-Aided Mol Des 17 (2003) 367-382
29. Richfield E.K. Quantitative autoradiography of the dopamine uptake complex in rat brain using [3H]GBR 12935 binding characteristics. Brain Res 540 (1991) 1-13
30. Rouge-Pont F., Abrous D.N., Le Moal M., and Piazza P.V. Release of endogenous dopamine in cultured mesencephalic neurons: influence of dopaminergic agonists and glucocorticoid antagonists. Euro J Neurosci 11 (1999) 2343-2350
31. Rudnick G. Mechanisms of biogenic amine neurotransmitter transporters. In: Reith M.E.A. (Ed). Neurotransmitter transporters: structure, function and regulation (2002), Humana Press, Totowa, NJ 25-52
32. Schroeter S., Apparsundaram S., Wiley R.G., Miner L.H., Sesack S.R., and Blakely R.D. Immunolocalization of the cocaine- and antidepressant-sensitive I-norepinephrine transporter. J Comp Neurol 420 (2000) 211-232
33. 2+ that require function of an N-methyl-d-aspartate receptor polyamine-sensitive site. Brain Res 995 (2004) 39-45
34. Singh S. Chemistry, design, and structure-activity relationship of cocaine antagonists. Chem Rev 100 (2000) 925-1024
35. Silvers J.M., Aksenova M.V., Aksenov M.Y., Mactutus C.F., and Booze RM. Neurotoxicity of HIV-1 Tat protein: involvement of D1 dopamine receptor. Neurotoxicology 28 (2007) 1184-1190
36. Silvers J.M., Aksenov M.Y., Aksenova M.V., Beckley J., Olton P., Mactutus C.F., et al. Dopaminergic marker proteins in the substantia nigra of human immunodeficiency virus type 1-infected brains. J Neurovirol 12 (2006) 140-145
37. Soucy J.-P., Mrini A., Lafaille F., Doucet G., and Descarries L. Comparative evaluation of [3H]WIN 35428 and [3H]GBR 12935 as markers of dopamine innervation density in brain. Synapse 25 (1997) 163-175
38. Sulzer D., and Galli A. Dopamine transport currents are promoted from curiosity to physiology. Trends Neurosci 26 (2003) 173-176
39. Thumen A., Qadri F., Sarkar R., and Moser A. GBR-12909 effect on dopamine outflow depends on phosphorylation in the caudate nucleus of the rat. Synapse 46 (2002) 72-78
40. Turchan J., Anderson C., Hauser K.F., Sun Q., Zhang J., Liu Y., et al. Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine. BMC Neurosci 2 (2001) 3
41. Van der Zee P., and Hespe W. Interaction between substituted 1-[2-(diphenylmethoxy)ethyl] piperazines and dopamine receptors. Neuropharmacology 24 (1985) 1171-1174
42. Valchar M., and Hanbauer I. Rat mesencephalic neuronal cells cultured for different periods as a model of dopamine transporter ontogenesis. Mol Neurobiol 11 (1995) 111-119
43. Vaughan R.A., Agoston G.E., Lever J.R., and Newman A.H. Differential binding of tropane-based photoaffinity ligands on the dopamine transporter. J Neurosci 19 (1999) 630-636
44. Vaughan R.A., Sakrikar D.S., Parnas M.L., Adkins S., Foster J.D., Duval R.A., et al. Localization of cocaine analog [125I]RTI 82 irreversible binding to transmembrane domain 6 of the dopamine transporter. J Biol Chem 282 (2007) 8915-8925
45. Wallace D.R., Dodson S., Nath A., and Booze R.M. Estrogen attenuates gp120- and tat (1-72)-induced oxidative stress and prevents loss of dopamine transporter function. Synapse 59 (2005) 51-60
46. Wang J.-G., Chang L., Volkow N., Telang F., Logan J., Ernst T., et al. Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 127 (2004) 2452-2458
47. 3H-GBR 12935 are differentially regulated by chronic cocaine self-administration. J Neurosci 14 (1994) 2966-2979
48. Xu C., Coffey L.L., and Reith M.E. Translocation of dopamine and binding of 2 beta-carbomethoxy-3 beta-(4-fluorophenyl) tropane (WIN 35,428) measured under identical conditions in rat striatal synaptosomal preparations inhibition by various blockers. Biomed Pharmacol 49 (1995) 339-350